骨髄穿刺濃縮液の世界市場：2024～2031年

概要

世界の骨髄穿刺濃縮液市場は、2023年に1億7,560万米ドルに達し、2031年には2億6,370万米ドルに達すると予測され、予測期間2024-2031年にはCAGR5.3%で成長する見込みです。

骨髄穿刺濃縮液（BMAC）は、骨再生に有用な生物学的産物である可能性があります。骨髄濃縮液は、成熟した骨成長を促進する補完物として整形外科で使用されています。骨髄吸引液は細胞、サイトカイン、成長因子豊富な供給源であり、吸引液を濃縮することにより、骨成長と軟部組織再生ため成長因子を利用することができます。

これら成分には抗炎症作用や再生作用があると考えられており、BMACはさまざまな筋骨格系疾患、特に変形性関節症や軟骨欠損に対する革新的な治療法となります。骨髄穿刺濃縮液は、主に造血細胞、脂肪組織、支持性間質細胞からなる骨髄に由来します。

骨髄にはごく一部（0.001％～0.01％）間葉系幹細胞（MSCs）が含まれており、組織再生と修復に極めて重要です。BMACは、吸引した骨髄を遠心分離し、MSCsやそ他有益な成分を含むバフィーコートと、赤血球やそ他不要な成分を分離することによって調製されます。

市場力学

促進要因

整形外科疾患とスポーツ傷害の増加

世界の骨髄穿刺濃縮液市場の需要は、複数の要因によって牽引されています。市場を牽引する主な要因の一つは、スポーツ傷害と整形外科疾患の発生率の増加です。ジョンズ・ホプキンス医学によると、2024年には、14歳以下の350万人以上の子供がスポーツ外傷を負い、骨にひびが入る可能性があります。

2024年2月のScientific Reports調査発表によると、変形性膝関節症の患者に血小板豊富血漿（PRP）または骨髄吸引濃縮物（BMAC）注射を行った場合、ヒアルロン酸を行った場合よりも良好な転帰を示します。

BMAは、筋骨格系の損傷における組織再生に好影響を示す様々な細胞成分や分子成分を豊富に含んでいます。これにより、骨粗鬆症性骨、嚢胞、不全骨折などの骨欠損の治療にBMAをタクトセットに組み合わせることで、タクトセットの商業的リーチが拡大します。

例えば、2023年1月、RegenOrthoSport社は、筋骨格系障害（MSD）に罹患した患者に対して併用療法を実施するために必要なすべての規制当局の承認を、保健家族福祉省傘下の国立倫理委員会生物医学・健康研究登録（NECRBHR）から取得したと発表しました。

関節炎、靭帯断裂、捻挫、挫傷、スポーツ傷害に苦しむMSD患者に対する自己BMAC-PRP併用アプローチ。

制約

ドナーの入手可能性が限られていること、治療の失敗率が高いこと、熟練した専門家が不足していること、製造コストが高いこと、規制要件が厳しいことなどが、市場の妨げになると予想されます。

目次

第1章 調査手法と調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 影響要因
  • 促進要因
    • 整形外科疾患とスポーツ傷害の増加
    • ヘルスケア支出の増加
  • 抑制要因
    • ドナーの入手可能性の制限
    • 治療の高い失敗率
  • 機会
  • 影響分析

第5章 産業分析

• ポーターのファイブフォース分析
• サプライチェーン分析
• 価格分析
• 規制分析
• アンメットニーズ
• PESTEL分析
• 特許分析
• SWOT分析

第6章 COVID-19分析

第7章 製品タイプ別

• 骨髄吸引濃縮システム
• 骨髄穿刺濃縮液アクセサリー

第8章 用途別

• 整形外科
• 創傷治癒
• 末梢血管疾患
• その他

第9章 エンドユーザー別

• 病院・クリニック
• 製薬・バイオテクノロジー企業
• 開発業務受託機関（CRO）および製造業務受託機関（CMO）
• 学術・研究機関

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他南米
• アジア太平洋
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• 中東・アフリカ

第11章 競合情勢

• 競合シナリオ
• 市況/シェア分析
• M&A分析

第12章 企業プロファイル

• Zimmer Biomet
  • 会社概要
  • 製品ポートフォリオと説明
  • 財務概要
  • 主な発展
• Terumo BCT, Inc
• Zoetis Services LLC
• Arthrex, Inc
• Globus Medical
• Royal Biologics
• Regen Lab SA
• AcCellerated Biologics
• Isto Biologics
• Stryker

第13章 付録

Overview

The global bone marrow aspirate concentrates market reached US$ 175.6 million in 2023 and is expected to reach US$ 263.7 million by 2031, growing at a CAGR of 5.3% during the forecast period 2024-2031.

Bone marrow aspirate concentrate (BMAC) is a potentially useful biological product for bone regeneration. Bone marrow concentrate is used in orthopedics as a complement to facilitate mature bone growth. Bone marrow aspirate is a rich source of cells, cytokines, and growth factors, and concentrating the aspirate helps harness the growth factors for bone growth and soft tissue regeneration.

These components are believed to have anti-inflammatory and regenerative properties, making BMAC an innovative treatment for various musculoskeletal conditions, particularly osteoarthritis and cartilage defects. Bone marrow aspirate concentrate is derived from the bone marrow, which is primarily composed of hematopoietic cells, adipose tissue, and supportive stromal cells.

The bone marrow contains a small fraction (0.001% to 0.01%) of mesenchymal stem cells (MSCs), which are crucial for tissue regeneration and repair. BMAC is prepared by centrifuging the aspirated bone marrow to separate the buffy coat, which contains the MSCs and other beneficial components, from the red blood cells and other unwanted elements.

Market Dynamics

Drivers

Increasing Prevalence of Orthopedic Diseases and Sports Injuries

The demand for the global bone marrow aspirate concentrates market is driven by multiple factors. One of the key factors driving the market is the increase in the incidence of sports injuries & orthopedic diseases. In 2024, as per Johns Hopkins Medicine, more than 3.5 million children aged 14 and below sustain sports injuries, which can cause the bones to crack.

As per Scientific Reports research publication in February 2024, patients with knee osteoarthritis who receive platelet-rich plasma (PRP) or bone marrow aspirate concentrate (BMAC) injections have better outcomes than patients who receive hyaluronic acid.

BMA is a rich source of various cellular and molecular components that have demonstrated positive effects on tissue regeneration in musculoskeletal injuries. This increases Tactoset's commercial reach by combining BMA with Tactoset for the treatment of bone defects such as osteoporotic bone, cysts, and insufficiency fractures.

For instance, in January 2023, RegenOrthoSport announced that it had obtained all necessary regulatory approvals from the National Ethics Committee Registry for Biomedical and Health Research (NECRBHR) under the Ministry of Health and Family Welfare for carrying out combination therapies on patients affected with Musculoskeletal Disorders (MSD).

Autologous BMAC-PRP combination approach on MSD patients who are suffering from arthritis, ligament tears, sprains, strains, and sports injuries.

Restraints

Factors such as the limited availability of donors, the high failure rate of the treatment, the lack of skilled professionals, the high cost of production, and stringent regulatory requirements are expected to hamper the market.

For more details on this report - Request for Sample

Segment Analysis

The global bone marrow aspirate concentrates market is segmented based on product type, application, end-user, and region.

The orthopedic surgery segment accounted for approximately 37.5% of the global bone marrow aspirate concentrates market share

The orthopedic surgery segment is expected to hold the largest market share over the forecast period owing to the increasing number of musculoskeletal disorders and the innovations in treating such disorders. There has been a rise in the number of osteoporosis cases worldwide.

According to the Journal of Climacteric publication in January 2022, osteoporosis causes more than 8.9 million fractures worldwide, resulting in an osteoporotic fracture every 3 seconds. The publication indicated that osteoporosis affected 200 million women worldwide as of January 2022. The large number of people affected by bone disorders is expected to add to the market growth.

Bone marrow aspirate concentrate (BMAC) is now commonly used in orthopedic surgery. Recent studies showed promising results for cartilage, bone, and soft tissue healing, however, many of these outcomes have yet to be translated into human models. While there has been an increase in the use of BMAC in foot and ankle procedures, the associated clinical evidence is limited.

Similarly, in April 2022, EurekAlert new release states that the regenerative potential of solid bone marrow aspirate concentrate is a new study compares the regenerative potential of blood/bone marrow aspirate concentrates obtained from arterial blood, venous blood, and bone marrow aspirate. Blood concentrate material such as platelet-rick fibrin (PRF) is used in clinical practice to promote tissue regeneration in the fields of dentistry, orthopedic surgery, and plastic surgery.

In addition, major key players in the industry launching innovative treatments would propel this segment's growth. For instance, in May 2024, the hospital for special surgery launched a clinical trial that will evaluate the efficacy of concentrated bone marrow aspirate can preventing chronic inflammation and osteoarthritis in ACL revision.

Geographical Analysis

North America accounted for approximately 42.3% of the global bone marrow aspirate concentrates market share

North America region is expected to hold the largest market share over the forecast period owing to the rising prevalence of osteoarthritis diseases, technological advancements, and government awareness initiatives that drive this market growth in this region.

In the U.S., Arthritis is a serious health crisis. CDC estimates in 2024, 1 in 5 (or 53.2 million) U.S. adults have some form of arthritis. While there are estimated to be more than 100 types of arthritis, osteoarthritis (OA) is the most common form of arthritis, affecting 32.5 million U.S. adults.

Moreover, key player innovative studies related to BMAC and launch in the region help to drive this market growth. For instance, in April 2022, the general hospital corporation study stated that the bone marrow aspirate promising for treating hip arthroscopy.

This study compared two strategies for preserving full-thickness chondral flaps during hip arthroscopy microfracture, and the use of bone marrow aspirate concentrate to bridge the chondral flap to the subchondral bone Both the microfracture and bone marrow aspirate concentrate (BMAC) cohorts experienced significant improvements in International Hip Outcome Tool-33 (iHOT-33) scores from baseline to the 12-month follow-up visit.

Also, in June 2022, Royal Biologics announced the FDA 510K regulatory clearance and U.S. commercial launch of the MAYY -BMC system. This system is a bone marrow aspirate concentration system that provides users with an optimal sample of concentrated bone marrow aspirate, from a patient, point of care.

COVID-19 Impact Analysis

The COVID-19 pandemic significantly impacted the global bone marrow aspirate concentrates market. In COVID-19 patients, bone marrow aspirate shows histiocytic proliferation with hemophagocytosis.

Several elective and non-urgent surgeries and therapies were either postponed or canceled, which negatively affected the growth of the bone marrow aspirate concentrate market. For instance, an article published in the Annals of Rheumatic Diseases in January 2021 indicated that during the COVID-19 pandemic, people with musculoskeletal disorders were advised not to seek emergency treatment because of fear of getting contaminated with the SARS-Cov-2 virus.

Market Segmentation

By Product Type

• Bone Marrow Aspirate Concentrates Systems
• Bone Marrow Aspirate Concentrates Accessories

By Application

• Orthopedic Surgery
• Wound Healing
• Peripheral Vascular Disease
• Others

By End-User

• Hospitals & Clinics
• Pharmaceutical & Biotechnology Companies
• Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
• Academic & Research Institutes

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the bone marrow aspirate concentrate market include Zimmer Biomet, Terumo BCT, Inc., Zoetis Services LLC, Arthrex, Inc., Globus Medical, Royal Biologics, Regen Lab SA, AcCellerated Biologics, Isto Biologics, Stryker among others.

Key Developments

• In April 2024, Scopio Labs announced that it had been granted De Novo clearance by the U.S. Food and Drug Administration (FDA) for its Full-Field Bone Marrow Aspirate (FF-BMA) Application. This marks a pivotal moment, establishing a new regulatory category for all-digital bone marrow aspirate analysis software.
• In April 2023 - Anika Therapeutics, Inc. announced that it had received an additional 510(k) clearance from the FDA for Tactoset Injectable Bone Substitute. This new indication expands the use of Tactoset to be combined with autologous bone marrow aspirate.
• In September 2022, Scopio Labs announced the launch of the Full-Field Bone Marrow Aspirate (FF-BMA) Application. This platform is the first to enable a complete digital workflow for bone marrow aspirate scanning and analysis.
• In August 2022, Cleveland Clinic Florida researchers are launching the first-ever phase III clinical trial researching the effects of BMAC versus triamcinolone in patients with hip osteoarthritis.

Why Purchase the Report?

• To visualize the global bone marrow aspirate concentrates market segmentation based on product type, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development
• Excel data sheet with numerous data points of global bone marrow aspirate concentrates market level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping is available in excel consisting of key products of all the major players.

The global bone marrow aspirate concentrates market report would provide approximately 62 tables, 53 figures, and 182 Pages.

Target Audience 2024

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Application
• 3.3. Snippet by End-User
• 3.4. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Increasing Prevalence of Orthopedic Diseases and Sports Injuries
    • 4.1.1.2. Rise in Healthcare Expenditure
  • 4.1.2. Restraints
    • 4.1.2.1. Limited Availability of Donors
    • 4.1.2.2. The High Failure Rate of the Treatment
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Unmet Needs
• 5.6. PESTEL Analysis
• 5.7. Patent Analysis
• 5.8. SWOT Analysis

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During the Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Product Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 7.1.2. Market Attractiveness Index, By Product Type
• 7.2. Bone Marrow Aspirate Concentrates Systems *
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Bone Marrow Aspirate Concentrates Accessories

8. By Application

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 8.1.2. Market Attractiveness Index, By Application
• 8.2. Orthopedic Surgery *
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Wound Healing
• 8.4. Peripheral Vascular Disease
• 8.5. Others

9. By End-User

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 9.1.2. Market Attractiveness Index, By End-User
• 9.2. Hospitals & Clinics *
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 9.3. Pharmaceutical & Biotechnology Companies
• 9.4. Contract Research Organizations (CROs) & Contract Manufacturing Organizations (CMOs)
• 9.5. Academic & Research Institutes

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. UK
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia-Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. South Korea
    • 10.5.6.5. Rest of Asia-Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
  • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
  • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape

• 11.1. Competitive Scenario
• 11.2. Market Positioning/Share Analysis
• 11.3. Mergers and Acquisitions Analysis

12. Company Profiles

• 12.1. Zimmer Biomet *
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio & Description
  • 12.1.3. Financial Overview
  • 12.1.4. Key Developments
• 12.2. Terumo BCT, Inc
• 12.3. Zoetis Services LLC
• 12.4. Arthrex, Inc
• 12.5. Globus Medical
• 12.6. Royal Biologics
• 12.7. Regen Lab SA
• 12.8. AcCellerated Biologics
• 12.9. Isto Biologics
• 12.10. Stryker

LIST NOT EXHAUSTIVE

13. Appendix

• 13.1. About Us and Services
• 13.2. Contact Us